Data - Pinpointing the implications of Big Five Personality Factors in moderating adjunctive antidepressant treatment response in a comparative study of esketamine and racemic ketamine for treatment-resistant depression.

Published: 03-12-2020| Version 1 | DOI: 10.17632/5yhxtvcgyy.1
Thais Rabanea-Souza,
Henrique Akiba,
Ana Paula Jesus-Nunes ,
Flávia Vieira,
Roberta Marback,
Ana Lucchese,
Sheila Cirigola,
Ana Teresa Caliman-Fontes,
Breno Souza-Marques,
Cassio Santos-Lima,
Fernanda Correia-Melo,
Gustavo Leal,
José Del-Porto,
Luciana Sarin,
Lucas Quarantini,
Acioly Lacerda


The prevalence of resistance to treatment with antidepressants remains high among patients with Major Depressive Disorder. Several studies have shown that ketamine/esketamine appears to be a very promising approach to treatment-resistant depression (TRD) and examining personality dimensions based on the theory of Goldberg's Big Five factors of personality have attracted increasing attention in moderating antidepressant response. This is a randomized, double-blind, active-controlled, bicentre, non-inferiority clinical trial, with two parallel groups. A total of 63 individuals, 18 years or older, with major depression characterized as treatment-resistant, were randomly assigned to a 40-min single intravenous infusion of ketamine 0.5 mg/kg (n=29) or esketamine 0.25 mg/kg (n=34). The NEO-FFI-R was used to assess the personality dimensions and MADRS was used to assess response, both were performed at baseline, at 24 hours and at 7 days following the single infusion of investigational products. In the logistic regression model, among the five personality factors only openness demonstrated statistically significant association with antidepressant response, as increased. Openness was associated with increased likelihood of response to treatment. GEE analysis comparing personality scores, across time and response to treatment showed reduction of neuroticism over time. Present findings suggest that the openness domain moderates ketamine/esketamine response in TRD.